Abstract
Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB.
Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further.
Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB.
Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
Keywords: Gestation, inflammation, lipopolysaccharide, N, N-dimethylacetamide, nuclear factor kappa B, preterm birth.
Current Pharmaceutical Design
Title:Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth
Volume: 24 Issue: 9
Author(s): Samir Gorasiya*, Juliet Mushi, Ryan Pekson, Sabesan Yoganathan and Sandra E. Reznik
Affiliation:
- Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences St. John`s University, Queens, NY 11439,United States
Keywords: Gestation, inflammation, lipopolysaccharide, N, N-dimethylacetamide, nuclear factor kappa B, preterm birth.
Abstract: Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB.
Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further.
Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB.
Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.
Export Options
About this article
Cite this article as:
Gorasiya Samir *, Mushi Juliet , Pekson Ryan , Yoganathan Sabesan and Reznik E. Sandra , Repurposing N,N-Dimethylacetamide (DMA), a Pharmaceutical Excipient, as a Prototype Novel Anti-inflammatory Agent for the Prevention and/or Treatment of Preterm Birth, Current Pharmaceutical Design 2018; 24 (9) . https://dx.doi.org/10.2174/1381612824666180130121706
DOI https://dx.doi.org/10.2174/1381612824666180130121706 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Synthetic Vitamin D Analogs with Antiproliferative Activities
Current Pharmaceutical Design Management of Inflammatory Bowel Disease Using Stem Cell Therapy
Current Stem Cell Research & Therapy Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing
Current Gene Therapy Nanotechnology and Diabetic Wound Healing: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Potentials of Triterpenes in Diabetes and its Associated Complications
Current Topics in Medicinal Chemistry Roadmap to Cellular Reprogramming – Manipulating Transcriptional Networks with DNA, RNA, Proteins and Small Molecules
Current Molecular Medicine Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Unravelling the Power of Omics for the Infertile Aging Male
Current Pharmaceutical Design Chemistry and Pharmacology of Neglected Helminthic Diseases
Current Medicinal Chemistry An Overview on Natural Polysaccharides with Antioxidant Properties
Current Medicinal Chemistry p53 is an Important Regulator of CCL2 Gene Expression
Current Molecular Medicine Therapies Targeting Innate Immunity for Fighting Inflammation in Atherosclerosis
Current Pharmaceutical Design Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Treatment Approaches for Swallowing Disorders in Children
Current Pediatric Reviews Identification of Novel Scaffolds for IκB Kinase Beta Inhibitor via a High Throughput Screening TR-FRET Assay
Combinatorial Chemistry & High Throughput Screening Identification of Enzyme Inhibitors from Phage-Displayed Combinatorial Peptide Libraries
Combinatorial Chemistry & High Throughput Screening Intravascular Targeting of a New Anticoagulant Heparin Compound
Cardiovascular & Hematological Disorders-Drug Targets Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Proteomic Studies on Plant-Pathogen Interaction in Compatible and Incompatible Systems
Current Proteomics